AI Driven ROI QuantX is an FDA-cleared AI based breast cancer decision support platform that delivers measurable ROI through faster reads and higher diagnostic accuracy. The platform supports a range of software solutions, including the QI Score and Similar Case Database Compare, enabling radiology teams to leverage lesion similarity to biopsy-proven results. Clinically, QuantX has demonstrated a 39% reduction in missed cancers and more than a 50% improvement in reading time for complex multi-modality cases, making it attractive for hospital and imaging-center buyers focused on outcomes and cost efficiency. The technology is licensed from the University of Chicago, underscoring clinical credibility.

Platform Advantage QuantX's exclusive QI Score and Similar Case Database Compare provide robust similarity-based assessment against biopsy-proven categories, offering a compelling value proposition for integration with existing radiology workflows and PACS. The platform orientation supports multiple software solutions, creating opportunities for OEM/IT partners and hospital-level pilots, particularly in breast cancer decision support deployments.

Credible Leadership Leadership credibility is reinforced by co-founder Maryellen Giger's iCON Innovator Award, which can facilitate engagement with academic medical centers and grant-funded pilots. Use this credential to cultivate early adopters among teaching hospitals and breast imaging programs and to secure co-development opportunities with research partners.

Partner-Driven Growth With a small team and early-stage revenue, scaling sales is well-suited to channel partnerships and OEM arrangements with imaging device manufacturers, PACS vendors, and imaging IT integrators. Pursue regional hospital network pilots and multi-site deployments to quickly demonstrate ROI and build reference sites.

Roadmap Potential The company signals a roadmap of deep learning based clinical solutions, indicating opportunities to expand beyond current breast cancer decision support into additional modalities or cancer types. This creates upsell potential with existing customers and invites collaborations with universities and academic medical centers to co-develop new AI tools for deployment within hospital systems.